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Abstract
Incorporating historical data or real-world evidence has a great potential to improve
the efficiency of phase I clinical trials and to accelerate drug development. For model-
based designs, such as the continuous reassessment method (CRM), this can be conveniently
carried out by specifying a “skeleton,” i.e., the prior estimate of dose limiting toxicity (DLT)
probability at each dose. In contrast, little work has been done to incorporate historical
data or real-world evidence into model-assisted designs, such as the Bayesian optimal interval
(BOIN), keyboard, and modified toxicity probability interval (mTPI) designs. This has led to
the misconception that model-assisted designs cannot incorporate prior information. In this
paper, we propose a unified framework that allows for incorporating historical data or real-
world evidence into model-assisted designs. The proposed approach uses the well-established
“skeleton” approach, combined with the concept of prior effective sample size, thus it is easy
to understand and use. More importantly, our approach maintains the hallmark of model-
assisted designs: simplicity—the dose escalation/de-escalation rule can be tabulated prior
to the trial conduct. Extensive simulation studies show that the proposed method can
effectively incorporate prior information to improve the operating characteristics of model-
assisted designs, similarly to model-based designs.
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1 Introduction
Recently, there has been tremendous interest in the use of prior information, such as historical
data or real-world evidence, as an effective approach to improve the efficiency of clinical trials.
In May 2019, the Food and Drug Administration (FDA) released a draft of guidelines for
submitting documents using real-world data or evidence to the FDA for drugs and biologics
[1]. When designing phase I trials, prior information is often available from previous studies.
For example, the drug to be investigated has been studied previously in other indications,
or similar drugs belonging to the same class have been studied in earlier phase I trials [2].
Another example is the proposal of bridging phase I trials to extend a drug from one ethnic
group (e.g., Caucasian) to another (e.g., Asian) [3], or from adult patients to pediatric
patients [4]. In this case, dose-toxicity data from the original trial in one ethnic group or
adult can be used to inform the design of the subsequent bridging trials, see for example Liu
et al. [3], Morita [5], and Li and Yuan [6].
Various phase I trial designs have been proposed to find the maximum tolerated dose
(MTD). These designs can be classified into algorithm-based, model-based, and model-
assisted designs, depending on their statistical foundations and implementation approaches.
Algorithm-based designs, such as the 3+3 design, are ad-hoc and simple to implement, but
also rigid, with poor accuracy to identify the MTD. It is difficult, if not impossible, to
incorporate prior information into algorithm-based designs. Model-based designs assume
a dose-toxicity model and determine the dose escalation/de-escalation by continuously up-
dating the estimate of the model based on accrued data. Typical examples of model-based
designs are the continual reassessment method (CRM [7]) and its variations, such as the esca-
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lation with overdose control [8], the Bayesian logistic regression model [9], and the Bayesian
model averaging CRM [10]. Model-based designs yield better performance than the 3+3
design in identifying and allocating more patients to MTD. Another important strength of
model-based designs is that they are straightforward to incorporate prior information. In
particular, for CRM, prior information can be easily incorporated by specifying a “skeleton”
of the dose-toxicity model—the prior estimate of dose limiting toxicity (DLT) probability
for each dose. More details are provided later. Along that line, Liu et al. proposed to
bridge CRM for phase I clinical trials in different ethnic populations based on Bayesian
model averaging [3]; Morita proposed to incorporate informative prior to CRM [5] ; Li and
Yuan proposed the continuous reassessment method for pediatric phase I oncology trials
(PA-CRM) to leverage trial information from adult trials to pediatric trials [6].
Model-assisted designs were developed to combine the simplicity of algorithm-based de-
signs with the superior performance of model-based designs. Similar to model-based designs,
model-assisted designs use a statistical model (e.g., the binomial model) to derive decision
rules for efficient decision making. And like algorithm-based designs, model-assisted de-
signs can have their dose escalation and de-escalation rules determined before the onset of
a trial, and thus can be implemented as simply as algorithm-based designs. Examples of
model-assisted designs include the Bayesian optimal interval (BOIN) design [11], the modi-
fied toxicity probability interval design (mTPI [12]), and the keyboard design [13] (or mTPI-2
[14]). Extensive numerical studies show that the model-assisted designs yield superior per-
formance comparable to more complicated model-based designs, and they are increasingly
used in practice [15].
Model-assisted designs were developed assuming a non-informative prior. Little research
has been done on how to incorporate informative prior information into the derivation of these
designs. This has led to the misconception that model-assisted designs cannot incorporate
informative prior information, which is sometimes cited as their weakness compared to model-
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based designs.
In this paper, we propose a unified framework to incorporate informative prior informa-
tion into model-assisted designs, including BOIN and keyboard (or equivalently, mTPI-2)
designs. Our method uses the skeleton approach similar to that in CRM, combined with
the concept of prior effective sample size (PESS) [16]. The method is intuitive and easy to
understand; more importantly, it maintains the simplicity of the model-assisted designs in
the sense that their dose escalation/de-escalation rule can still be determined and included
in the protocol before the onset of a trial. Numerical studies show that incorporating ap-
propriate informative prior information can improve the performance of the model-assisted
designs, similarly to CRM.
The remainder of the paper is organized as follows. In Section 2, we propose the method-
ology of incorporating informative prior information through skeleton and PESS for CRM,
BOIN, and keyboard designs. In Section 3, we provide the software to implement the pro-
posed designs. In Section 4, we conduct extensive simulation to evaluate the operating
characteristics of the proposed methodology. We conclude the study with a brief summary
in Section 5.
2 Method
2.1 Incorporate prior information in CRM
We first describe how to incorporate prior information in the CRM. Let j = 1, · · · , J , denote
the J doses under investigation, and pj denote the true DLT probability of dose j. The
objective of the trial is to find the MTD, whose DLT probability is equal or the closest to a
prespecified target DLT probability φ.
To incorporate prior information on the dose-toxicity relationship, we elicit the prior
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estimate of (p1, · · · , pJ), denoted as (q1, · · · , qJ), known as “skeleton.” The skeleton can be
estimated based on historical data or real-world evidence, e.g., by fitting a logistic model or
nonparametric model [3], or specified by clinicians based on their clinical experience. We
link pj with the skeleton through a parametric model
pj = q
exp(α)
j , for j = 1, · · · , J, (2.1)
where α is an unknown parameter that controls the discrepancy between the prior estimate
qj and the true DLT probability pj. Under the Bayesian paradigm, we assign α a normal
prior f(α) = N(0, σ2), where σ2 is a prespecified hyperparameter. As a result, a priori
the dose-toxicity curve (p1, · · · , pJ) centers around the skeleton (q1, · · · , qJ). The value of
σ2 controls the amount of information contained in the prior that can be borrowed from
historical data (i.e., the skeleton). A smaller value leads to stronger borrowing. If σ2 = 0,
the prior completely dominates the observed data, and pj ≡ qj regardless of the observed
data.
Let D = (D1, · · · , DJ) denote the observed data, where Dj = (nj, yj) denotes the data
observed at dose level j with nj being the number of patients treated and yj the number
of patients who experienced DLTs at dose j. To make the decision of dose escalation and
de-escalation, CRM updates the posterior estimate of pj as follows:
pˆj =
∫
q
exp(α)
j
L(D | α)f(α)∫
L(D | α)f(α)dαdα,
where L(D | α) = ∏Jj=1 {qexp(α)j }yj {1− qexp(α)j }nj−yj is the likelihood function, and f(α) =
N(0, σ2) is the prior distribution of α. Then, CRM assigns the next cohort of patients at the
dose whose pˆj is closet to φ. In practice, we typically impose safety rules, such as starting
at the lowest dose level and no dose skipping during dose escalation.
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Given a specific skeleton and prior f(α) = N(0, σ2), it is of great importance to quantify
how much information is borrowed from historical data. This is, however, rarely discussed in
the dose finding literature. In what follows, we propose a simple and intuitive approach to
formally quantify the information borrowed through the skeleton using the concept of prior
effective sample size (PESS), which represents the sample size that the prior information is
equivalent to. Morita et al. [16] proposed a general methodology to determine PESS, but
this approach requires complicated derivation and intensive simulation.
Our approach is simpler, more intuitive, and built upon the following observation: assum-
ing yj follows a binomial distribution Binom(nj, pj), if pj follows a beta prior distribution
Beta(a, b), then a + b can be interpreted as the PESS. Our strategy is to approximate the
prior distribution of pj, induced by model (2.1) and f(α), with a beta distribution by match-
ing the first and second moments. Therefore, PESS can be easily determined. Specifically,
given skeleton (q1, · · · , qJ) and prior f(α), let µj and τ 2j denote the prior mean and variance
of pj, respectively, with
µj =
∫
pjf(pj)dpj, τ
2
j =
∫
p2jf(pj)dpj − u2j ,
where f(pj) is the prior distribution of pj induced by the prior distribution of f(α) =
N(0, σ2), given by
f(pj) = − 1
2pi
exp
−
[
log
(
log(pj)
log(qj)
)]2
2σ2
 1pj log(pj) .
Matching the first and second comments of pj by a beta distribution Beta(aj, bj), we obtain
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the skeleton PESS as aj + bj, where
aj =
µ2j(1− µj)
τ 2j
− µj, bj = a(1− µj)
µj
. (2.2)
This reveals a property of CRM that is barely discussed in the literature, though it is
of great importance in practice. Because pj is a non-linear function of α, once prior f(α)
is specified, PESS for each dose is automatically determined. For example, given skeleton
(q1, · · · , q5) = (0.10, 0.19, 0.30, 0.42, 0.54) and prior f(α) = N(0, 0.72), PESS is (3, 3, 3,
3.1, 3.4) for the five doses. As a result, CRM does not allow users to specify dose-specific
prior information or PESS. However, in practice, we often have an unequal amount of prior
information for different doses. For example, we often have more data at the doses that are
below and around the MTD from historical phase I trials. In this case, it is highly desirable
to be able to specify a different PESS for each unique dose according to the historical data.
2.2 Incorporate prior information in BOIN
We now discuss how to use the skeleton, coupled with PESS, to incorporate prior information
into model-assisted designs such as BOIN. To do so, we first briefly describe the genesis of
the BOIN design, which lays the foundation for the proposed approach. Consider a class of
nonparametric designs Cnp as follows.
(a) Patients in the first cohort are treated at the lowest or a prespecified starting dose
level.
(b) At the current dose level j, let pˆj = yj/nj denote the observed DLT probability, and
λe (j, nj, φ) and λd (j, nj, φ) denote arbitrary functions of j, nj and φ, serving as the
dose escalation and de-escalation boundaries, respectively, with 0 ≤ λe (j, nj, φ) <
λd (j, nj, φ) ≤ 1. Use the following procedure to assign a dose to the next cohort of
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patients.
• Escalate the dose level to j + 1, if pˆj < λe (j, nj, φ);
• De-escalate the dose level to j - 1, if pˆj > λd (j, nj, φ);
• Stay at the same dose level, j, if λe (j, nj, φ) ≤ pˆj ≤ λd (j, nj, φ).
(c) This process is continued until the maximum sample size is reached.
Note that λe (j, nj, φ) and λd (j, nj, φ) can vary with dose level j, the number of patients
treated nj, and the target φ. This class of nonparametric designs includes all possible designs
that do not impose a parametric assumption on the dose-toxicity curve. For notational
brevity, in what follows, we suppress arguments in λe (j, nj, φ) and λd (j, nj, φ) and denote
them as λe and λd.
The BOIN design is obtained by choosing the optimal dose escalation and de-escalation
boundaries λe and λd to minimize the probability of making incorrect dose escalation and
de-escalation decisions. The optimization is carried out under three point hypotheses:
H1 : pj = φ; H2 : pj = φ1; H3 : pj = φ2,
where φ1 denotes the DLT probability that is deemed substantially lower than the target (i.e.,
underdosing) such that dose escalation should be made, and φ2 denotes the DLT probability
that is deemed substantially higher than the target (i.e., overdosing) such that dose de-
escalation is required. Thus, the correct decision under H1, H2, and H3 is stay, escalation,
and de-escalation, respectively; and other decisions are incorrect. For example, under H1,
escalation or de-escalation are incorrect decisions. Liu and Yuan (2015) showed that optimal
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dose escalation and de-escalation boundaries that minimize incorrect decisions are given by
λe = max
0, log
(
1−φ1
1−φ
)
+ n−1j log
(
pi2j
pi1j
)
log
{
φ(1−φ1)
φ1(1−φ)
}
 ,
λd = min
1, log
(
1−φ
1−φ2
)
+ n−1j log
(
pi1j
pi3j
)
log
{
φ2(1−φ)
φ(1−φ2)
}
 , (2.3)
where pikj = Pr(Hk) is the prior probability that the hypothesis Hk is true at dose level j,
where k = 1, 2, 3. As a result, BOIN is the optimal design with the lowest decision error
rate among all nonparametric designs. Liu and Yuan (2015) recommended default values
φ1 = 0.6φ and φ2 = 1.4φ, which lead to desirable operating characteristics and the decision
rule that fits most clinical practices.
When there is no reliable prior information available, we can take the non-informative
prior approach and assign the equal probability to each of the three hypotheses being true,
i.e., pi1j = pi2j = pi3j = 1/3. Then, the optimal boundaries (2.3) become
λ∗e =
log
(
1−φ1
1−φ
)
log
{
φ(1−φ1)
φ1(1−φ)
} and λ∗d = log
(
1−φ
1−φ2
)
log
{
φ2(1−φ)
φ(1−φ2)
} , (2.4)
which have the desirable feature that they are independent to the dose level j and the number
of patients treated nj. This means that the same pair of dose escalation and de-escalation
boundaries (λd, λe) can be used throughout the trial to make the decision of dose escalation
and de-escalation, making the BOIN design particularly simple to implement. That is, if
pˆj < λ
∗
e, escalate the dose; if pˆj > λ
∗
d, de-escalate the dose; otherwise, stay at the current
dose.
When prior information is available, we propose the following procedure to incorporate
it into the design:
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1. Elicit skeleton (q1, · · · , qJ) and corresponding PESS (n01, · · · , n0J), where n0j is the
desirable PESS for dose level j, j = 1, · · · , J .
2. Determine the informative prior for Hk, i.e., pikj, as
pikj =
n0∑
x=0
φxk(1− φk)n0−x∑3
k′=1 φ
x
k′(1− φk′)n0−x
(
n0
x
)
qxj (1− qj)n0−x. (2.5)
3. Make the decision of dose escalation or de-escalation according to the boundaries given
in (2.3) with pikj determined in step 2.
The derivation of pikj in step 2 is provided in Section A.1. We refer to the resulting design
(with informative prior) as iBOIN.
Because of the incorporation of the informative prior information, the escalation and de-
escalation boundaries λe and λd of iBOIN depend on the dose level j, as well as nj. Figure 1
contrasts the boundaries under a non-informative prior and those under an informative prior
for a trial with 5 doses and an elicited skeleton (0.10, 0.19, 0.30, 0.42, 0.54), when the target
DLT probability is 0.3 and PESS is 3 or 5. For example, because the prior information says
that the lowest dose is below the true MTD (with the prior DLT probability of 0.10), its
escalation boundary λe is higher than that of the non-informative prior to encourage dose
escalation. On the contrary, because the prior information says the highest dose is above
the MTD (with the prior DLT probability of 0.54), its de-escalation boundary λd is lower
than that of the non-informative prior to encourage dose de-escalation. The informative
decision boundaries approach to those in stadnard BOIN (with noninformative prior), when
the number of patients treated increases (i.e., data start to override prior information).
iBOIN becomes the standard BOIN, when (n01, · · · , n0J) = 0.
Compared to CRM, iBOIN is more flexible and allows users to accurately incorporate
prior information by specifying a PESS for each dose. For example, given a phase I trial
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with 5 doses, if historical data provide more information on the first 2 doses than the last
2 doses and most information on dose level 3, we could specify the 5 doses’ PESS as (3, 3,
6, 1, 1) to reflect that. As described previously, this is extremely difficult, if not impossible,
under CRM.
The other advantage of iBOIN is that the dose escalation and de-escalation rule can be
pre-tabulated and included in the trial protocol. Table 1 shows the decision table of iBOIN
with skeleton (0.10, 0.19, 0.30, 0.42, 0.54) and the effective sample size n01 = · · · = n05 = 3.
This decision table is equivalent to the rule based on λe and λd, but easier to use in practice.
Users need only identify the row corresponding to the current dose level, and then they
can use the boundaries listed in that row to easily make the decision of dose escalation and
de-escalation. In summary, the iBOIN design can be described as follows:
1. Patients in the first cohort are treated at the lowest dose d1, or the physician-specified
dose.
2. Given data (nj, yj) observed at the current dose level j, make the decision of escalation/de-
escalation according to the iBOIN decision table (e.g., Table 1) for treating the next
cohort of patients.
3. Repeat step 2 until the prespecified maximum sample size is reached, and then select
the MTD as the dose whose isotonically transformed estimate of pj is closest to φ.
For the purpose of overdose control, following BOIN, the iBOIN design imposes a dose
elimination rule: if Pr(pj > φ | yj, nj) > 0.95 and nj ≥ 3, dose level j and higher are
eliminated from the trial, where Pr(pj > φ | nj, yj) is evaluated based on the beta-binomial
model with the uniform(0, 1) prior. As the objective of the dose elimination rule is to protect
patients from excessively toxic doses, it is sensible to use the uniform prior to evaluate
this rule to avoid potential bias due to potential misspecification of the prior. The trial is
terminated if the lowest dose level is eliminated.
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At the end of the trial, iBOIN uses the isotonic estimate of pj to select the MTD (i.e., step
3). As determining dose escalation/de-escalation and selecting the MTD are two independent
components, when the trial is completed, other methods can also be used to determine the
MTD. For example, when desirable, we can fit a dose-toxicity model (e.g., a logistic model)
as CRM to select the MTD.
2.3 Incorporate prior information in keyboard/mTPI-2 design
The keyboard design is another model-assisted design, which was developed to address the
overdosing issue of the mTPI design. Guo et al. [14] proposed a modification of mTPI, known
as mTPI-2, which is statistically equivalent to the keyboard design, but less transparent and
relying upon a perplexing statistical concept and method (e.g., Occams razor and model
selection). Thus, we only present the keyboard design. The methodology described below is
directly applicable to mTPI and mTPI-2.
The keyboard design starts by specifying a proper dosing interval I∗ = (δ1, δ2), referred
to as the “target key,” and then populates this interval toward both sides of the target key,
forming a series of keys of equal width that span the range of 0 to 1. For example, given
a target rate of φ = 0.30, the proper dosing interval or target key may be defined as (0.25,
0.35), then on its left side, we form 2 keys of width 0.1, i.e., (0.15, 0.25) and (0.05, 0.15); and
on its right side, we form 6 keys of width 0.1, i.e., (0.35, 0.45), (0.45, 0.55), (0.55, 0.65), (0.65,
0.75), (0.75, 0.85) and (0.85, 0.95). We denote the resulting intervals/keys as I1, · · · , IK .
The keyboard design assumes a beta-binomial model,
yj |nj, pj ∼ Binom(nj, pj)
pj ∼ Beta(aj, bj), (2.6)
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where aj and bj are hyperparameters. The posterior distribution of pj arises as
pj |Dj ∼ Beta(yj + aj, nj − yj + bj), for j = 1, . . . , J. (2.7)
By default, the keyboard design set aj = bj = 1 to obtain a uniform prior. To make the
decision of dose escalation and de-escalation, given the observed data Dj = (nj, yj) at the
current dose level j, the keyboard design identifies the interval Imax that has the largest
posterior probability, i.e.,
Imax = argmaxI1,··· ,IK{Pr(pj ∈ Ik |Dj); k = 1, · · · , K}.
Imax represents the interval within which the true value of pj is most likely located, referred
to as the “strongest” key by Yan et al. [13]. Suppose j is the current dose level. The
keyboard design determines the next dose as follows.
• Escalate the dose to level j+ 1, if the strongest key is on the left side of the target key.
• Stay at the current dose level j, if the strongest key is the target key.
• De-escalate the dose to level j−1, if the strongest key is on the right side of the target
key.
The trial continues until the prespecified sample size is exhausted, and the MTD is selected
based on isotonic estimates of pj. During the trial conduct, the keyboard design imposes the
same dose elimination/early stopping rule as the BOIN design.
As in the beta-binomial model (2.6), aj + bj can be interpreted as the PESS. We propose
the following procedure to incorporate prior information into the keyboard design:
1. Elicit skeleton (q1, · · · , qJ) and corresponding PESS (n01, · · · , n0J), where n0j is the
desirable PESS for dose level j, j = 1, · · · , J .
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2. Determine hyperparameter aj and bj in the beta prior (2.6) as follows:
aj = n0jqj; bj = n0j(1− qj), j = 1, · · · , J (2.8)
3. Make dose escalation and de-escalation based on the resulting posterior given by equa-
tion (2.7).
We refer to the keyboard design with an informative prior as the iKeyboard design. Given a
fixed maximum sample size, all possible outcomes Dj = (nj, yj) can be enumerated, and for
each possible outcome, the posterior distribution f(pj|Dj) can be calculated. Therefore, the
dose escalation/de-escalation rule of iKeyboard can be tabulated. The decision table for the
iKeyboard design can also be pre-tabulated, similar to iBOIN. The above approach is directly
applicable to the mTPI design for incorporating prior information. As the keyboard/mTPI-2
design outperforms the mTPI design in both safety and accuracy (Yan et al., [13]; Guo et
al.[14]; Zhou et al. [17]), we will not discuss mTPI.
2.4 Robust prior
The performance of aforementioned designs is affected by whether the informative prior is
correctly specified. When the informative prior is correctly specified, it improves the accuracy
of identifying the MTD. However, when the informative prior is seriously misspecified, it may
compromise the accuracy of identifying the MTD. In the numerical study described later,
we found that the impact of the misspecification depends on both the location of the prior
MTD and the location of the true MTD. For example, consider two cases: in case 1, the
prior sets dose level 3 as the MTD, while the true MTD is dose level 5; and in case 2, the
prior sets dose level 1 as the MTD, while the true MTD is dose level 3. Although both priors
are misspecified by 2 dose levels, iBOIN and iKeyboard designs have a lower probability
14
of identifying the true MTD in case 1 than in case 2. This is because in case 2, the prior
MTD is dose level 1; there is sufficient sample size to override the prior and escalate to find
the true MTD. In contrast, in case 1, because the MTD is dose level 5, the sample size is
often exhausted before enough data are accumulated at dose level 3 (i.e., the prior MTD) to
override the prior, thus fails to find the true MTD with a high probability.
This observation motivated us to propose a robust prior, which is useful when there is
a great amount of uncertainty regarding the prior information. Given the elicited skeleton
(q1, · · · , qJ) with dose level j∗ as the prior estimate of the MTD (i.e., qj∗ = φ), the ro-
bust prior is the same as the prior described above when j∗ < J/2, but modify PESS to
(n01, · · · , n0j∗ , 0, · · · , 0) when j∗ ≥ J/2. In other words, when prior MTD j∗ ≥ J/2, the
robust prior uses informative prior information for the dose up to the prior estimate of the
MTD, and after that it uses the non-informative prior. This modification facilitates overrid-
ing the prior when the data conflict with the prior, and thus alleviates the impact of prior
misspecification. Our simulation study described later shows that the iBOIN and iKeyboard
designs are robust to moderate misspecification of priors, and using the robust prior proves
their robustness when the prior is severely misspecified.
Another way to robustify the prior is to use mixture [?]. Let piinf and pinon gener-
ically denote the informative prior (obtained based on the skeleton and PESS) and the
non-informative prior described previously. The mixture prior is given by pimix = wpiinf +
(1− w)pinon, where 0 ≤ w ≤ 1 is a prespecified mixture proportion. If the prior information
is reliable, we assign w a large value (e.g., w = 0.9); and if the prior information has high
uncertainty, we assign w a small value (e.g., w = 0.5). Numerical study shows that the
mixture prior does not perform as well as the aforementioned robust prior (see Appendix
A.4 for simulation results), thus hereafter we focus on the latter.
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2.5 Choose PESS
PESS should be chosen to reflect the appropriate amount of prior information to be incor-
porated, which depends on the reliability of the prior information and varies from trial to
trial. When there is strong evidence that the prior is most likely correctly specified, it is
appropriate to use a large PESS to borrow more information; when there is a great amount
of uncertainty regarding whether the prior is most likely correctly specified, we may use a
small PESS to avoid bias. In practice, there is often sizable uncertainty on the reliability of
the prior information. Thus, PESS should be chosen carefully to achieve an appropriate bal-
ance between design performance and robustness. Using a large PESS improves the design
performance (i.e., the accuracy to identify the MTD) when the prior is correctly specified,
but may lead to a substantial loss of performance when the prior is severely misspecified.
Based on numerical study, we recommend PESS ∈ [1/3(N/J), 1/2(N/J)] as the default value
that improves trial performance while maintaining reasonably robust. For example, when
J = 5 and N = 30, the recommended value for PESS is n0j = 2 or 3 (i.e., across 5 doses,
the total PESS is 10 or 15). The value of n0j can be further calibrated by simulation using
the software described in the next section.
3 Software
We have developed the online software “BOIN Suite” to allow users to design trials, conduct
simulations, and generate protocol templates. The software has an intuitive graphical user
interface and rich documents to help with navigating through the process, see Figure A.1 for
the user interface of the software, which is freely available at https://www.trialdesign.org. A
trial can be easily designed via the following three steps.
Step 1. Specify the design parameters, e.g., sample size, cohort size, target DLT prob-
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ability, skeleton, and PESS.
Step 2. Use the software to produce a decision table and design diagram, and conduct
simulation to obtain the operating characteristics of the design. The software also gen-
erates sample texts and protocol templates to facilitate writing the protocol.
Step 3. Use the design decision table to conduct the trial.
After a trial completes, use the app to select the MTD.
4 Simulation
We conducted extensive simulations to evaluate the operating characteristics of the proposed
designs. We assumed J = 5 doses and the target DLT probability φ = 0.3. The maximum
sample size was N = 30 with a cohort size of 3. We considered the CRM with an informative
prior (denoted as iCRM), iBOIN, and iKeyboard, as well as their counterparts with a non-
informative prior. We also considered BOIN and Keyboard designs with the robust prior,
denoted as iBOINR and iKeyboardR, respectively. For iBOIN and iKeyboard, we set PESS
n0j = 3 for j = 1, · · · 5; and for iCRM, the prior is chosen such that the PESS at the prior
MTD is 3. All the designs use the same skeletons (i.e., the prior DLT probabilities), which
are provided in Table 2.
4.1 Fixed scenarios
We evaluated the performance of the designs in ten scenarios, as shown in Table 2. In the
first five scenarios, the MTD was located at dose level 1, 2, 3, 4 and 5, respectively; and
the prior MTD was correctly specified and matched the true MTD. To reflect the practice,
we did not assume that the prior (at each dose level) exactly matched the truth. Here, we
called a prior correctly specified if the prior MTD matched the true MTD. Scenarios 6-10
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considered the cases that the prior was misspecified. Specifically, in scenarios 6 and 7, the
prior MTD was one level off from the true MTD, and in scenarios 8-10, the prior MTD was
two levels off from the true MTD.
Table 3 shows the results, including (1) percentage of correct selection (PCS), defined as
the percentage of simulated trials in which the MTD is correctly identified; (2) percentage
of patients treated at MTD; (3) percentage of patients treated above MTD; (4) risk of
overdosing, defined as the percentage of simulated trials that assigned 50% or more patients
to doses above MTD; and (5) risk of poor allocation, defined as the percentage of simulated
trials that assigned less than six patients to MTD. As noted by Zhou et al. [18], metrics
(4) to (5) measure the reliability of the design, i.e., the likelihood of a design demonstrating
extreme problematic behaviors (e.g., treating 50% or more patients at toxic doses, or fewer
than six patients at the MTD), which are of great practical importance. Note that the
percentage of patients overdosed (i.e., metric (3)) does not cover the risk of overdosing (i.e.,
metric (4)). Two designs can have a similar percentage of patients overdosed, but rather
different risks of overdosing 50% of the patients.
In scenarios 1 to 5, the prior was correctly specified. iCRM and iBOIN outperformed
their counterparts that use non-informative priors. Specifically, compared to CRM, iCRM
improved PCS and the percentage of patients treated at MTD by 2-8% and 3-6%, respec-
tively. Compared to BOIN, iBOIN improved PCS and the percentage of patients treated at
MTD by 5-8% and 5-7%, respectively. iCRM and iBOIN yielded comparable PCS and the
percentage of patients assigned to MTD, but iBOIN was more reliable with a lower risk of
overdoing. For example, in scenarios 2 and 3, the risk of overdosing for iBOIN was about half
and one fourth of that for iCRM, respectively. Compared to its non-informative counterpart,
iKeyboard had a 5-13% increase in PCS, but the percentage of patients treated at MTD was
often lower and the risk of overdosing was substantially increased by more than 10% in most
scenarios. iBOINR and iKeyboardR yielded similar performances to iBOIN and iKeyboard,
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respectively.
Scenarios 6 and 7 considered the cases where the prior was misspecified, with the prior
MTD being one level off from the true MTD. iCRM and iBOIN were robust to this moderate
prior misspecification and outperformed their counterparts. For example, in scenario 6, the
PCS of iCRM and iBOIN were 57.3% and 58.6%, respectively; this was 6.6% and 7.1% higher
than CRM and BOIN. Compared to iCRM, iBOIN had a lower overdose risk. Scenarios 8 and
9 examined the cases where the prior was severely misspecified, with the prior MTD being
two levels off from the true MTD. When the prior MTD was higher than the true MTD (i.e.,
scenario 8), iCRM and iBOIN performed well, yielding performances comparable to their
non-informative counterparts. The PCS of iKeyboard was lower than keyboard. When the
prior MTD was lower than the true MTD (i.e., scenario 9), the prior misspecification had
more impact on the performance of the designs. The PCS of iCRM and iBOIN was lower
than their non-informative counterparts. Scenario 9 was a difficult scenario, because the true
MTD was the highest dose. The sample size was often exhausted before enough data were
accumulated to overcome the misspecified prior to reach the highest dose (i.e., MTD). In this
scenario, iCRM performed better than iBOIN because the iCRM tended to escalate the dose
more aggressively, as demonstrated by its relatively high risk of overdosing. The proposed
robust prior addressed this issue. iBOINR yielded a higher PCS, comparable to standard
BOIN. In the case that the prior MTD was two levels lower than the true MTD, but the
true MTD was not the highest dose, iCRM and iBOIN outperformed their non-informative
counterparts (see scenario 10).
4.2 Random scenarios
To validate the above results, we repeated the simulation using a large number of scenar-
ios randomly generated using a pseudo-uniform algorithm [19]. Two large sets of random
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scenarios were constructed. The first set was used to examine the operating characteristics
of the designs when the prior was correctly specified. We generated 2000 random scenarios
with MTD located at dose level 1, 2, 3, 4, and 5, with equal probability, and we assumed that
the prior MTD was correctly specified for each of the scenarios. The second set was used to
evaluate the performance of the designs when the prior was misspecified. We considered two
types of misspecification: the prior MTD was one level off from the true MTD, and the prior
MTD was two levels off from the true MTD. For each type of misspecification, we generated
4000 random scenarios with half of them having the prior MTD (one or two levels) lower
than the true MTD, and the other half having the prior MTD (one or two levels) higher
than the true MTD. We simulated 2000 trials for each scenario. Details on random scenario
generation and configuration are provided in Section A.3.
Figure 2 shows the simulation results when the prior MTD was correctly specified. The
findings were generally consistent with the results based on the fixed scenarios. That is,
iCRM and iBOIN outperformed their non-informative counterparts with a higher PCS and
a higher percentage of patients assigned to MTD. For example, averaging over 2000 random
scenarios, the PCS of iCRM was 7% higher than that of the CRM, and the PCS of iBOIN
is 8% higher than that of BOIN. iCRM and iBOIN yielded similar PCS and percentage of
patients to the MTD, but iBOIN had a lower risk of overdosing and poor allocation. The
iKeyboard design yielded a higher PCS than its non-informative counterpart, but increased
the risk of overdosing due to its aggressive dose escalation.
Figure 3 shows the simulation results when the prior was misspecified by one dose level.
iCRM and iBOIN proved robust to such moderate prior misspecification. The PCS of iCRM
and iBOIN were both 56%, offering 3% and 5% improvement over their non-informative
counterparts, respectively. The risk of overdosing and poor allocation for iCRM were respec-
tively 5% and 6% higher than that for iBOIN. The iKeyboard design offered 3% improvement
over its non-informative counterpart, but the risk of overdosing was 8% higher. When the
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prior was severely misspecified with the prior MTD being two levels off from the true MTD
(see Figure 4), iCRM was more robust than iBOIN; however, by using the proposed robust
prior, iBOINR showed competitive performance. In practice, when the prior is likely to be
severely misspecified, using prior information should be avoided in favor of the more sensible
non-informative prior.
4.3 Unequal prior information across doses
Lastly, we briefly investigated the case that different amounts of prior information were
available for different doses. We assumed that more prior data were available at lower doses
than higher doses, and more prior data were available around the prior MTD, as we often
observed in (historical) phase I trials. As described in Section 2, iBOIN can easily accom-
modate this by specifying different PESS at different doses. Figure 5 shows the simulation
results under scenarios 1 to 5. We controlled the total PESS over five doses as the same
for iBOIN and iCRM (i.e., CRM). We see that, compared to CRM, iBOIN offered a higher
PCS and allocated a larger percentage of patients at the MTD, as well as a lower risk of
overdosing and poor allocation. CRM does not allow for specifying dose-specific PESS as
it uses a single parameter to control prior information in all doses, thus it cannot take full
advantage of the prior information.
5 Conclusion
In this paper, we propose a unified framework to incorporate historical data or real-world
evidence to improve the efficiency of phase I trial designs, especially model-assisted designs.
By using skeleton and PESS, our method is intuitive and easy to interpret. More im-
portantly, our approach maintains the hallmark of model-assisted designs: simplicity—the
dose escalation/de-escalation rule can be tabulated prior to the trial conduct. For exam-
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ple, implementing the proposed iBOIN only involves a simple comparison of the number of
DLTs observed at the current dose with the prespecified dose escalation and de-escalation
boundaries (e.g., Table 1). Extensive simulation studies show that the proposed method, in
particular iBOIN, can effectively incorporate prior information and yield comparable per-
formance as the model-based CRM design, but with greater reliability. Moreover, iBOIN is
more transparent and easier to implement. In addition, iBOIN has greater flexibility and
allows for specifying dose-specific prior information to more accurately reflect available prior
information. The iBOIN design is generally robust to prior misspecification. When there is a
high likelihood that the prior is severely misspecified, the proposed robust prior can be used
with iBOIN to enhance its robustness. Actually, in this case, there is little rationale to in-
corporate prior information and it is more appropriate to use a non-informative prior. When
non-informative prior is used, iBOIN becomes standard BOIN. Freely available software is
provided at https://www.trialdesign.org to facilitate the use of proposed designs.
The proposed methodology requires prespecification of skeleton and PESS. Investigators
often have good knowledge on the skeleton, e.g., obtained by fitting a model to historical
data, but less knowledge on the PESS. Thus in some applications, investigators may have
difficulty to specify the PESS or worry about the accuracy of the PESS. In general, we
do not regard this as an issue in practice. Our numerical study shows that the proposed
designs are remarkably robust. In addition, as it is undesirable to let prior information
dominate the trial data, the range for the reasonable PESS actually is narrow, typically
within [0, 6], given small sample size of phase I trials. In the case that investigators have
difficulty to choose the PESS, our recommended PESS ∈ [1/3(N/J), 1/2(N/J)] is a good
choice, in particularly used with the proposed robust prior. Other approaches might be
taken to further alleviate this issue. For example, rather than eliciting a value of PESS,
we can ask clinicians to provide a prior distribution of the PESS, e.g., Pr(PESS=1)=0.2,
Pr(PESS=2)=0.6 and Pr(PESS=3)=0.2, to incorporate their uncertainty on the PESS. The
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other possible approach is to adjust the PESS adaptively using two-stage design. The first
stage uses the prespecified PESS. At the end of the first stage, if the observed interim data
show the evidence of conflicting with the skeleton, we may discount the PESS for conducting
the second stage of dose-finding. These approaches warrant further research.
23
References
[1] US Food, Drug Administration, et al. Submitting documents using real-world data
and real-world evidence to fda for drugs and biologics: Guidance for industry: Draft
guidance. Rockville, MD: US Food and Drug Administration, 2019.
[2] Sarah Zohar, Sandrine Katsahian, and John O’Quigley. An approach to meta-analysis
of dose-finding studies. Statistics in Medicine, 30(17):2109–2116, 2011.
[3] Suyu Liu, Haitao Pan, Jielai Xia, Qin Huang, and Ying Yuan. Bridging continual
reassessment method for phase I clinical trials in different ethnic populations. Statistics
in Medicine, 34(10):1681–1694, 2015.
[4] Caroline Petit, Adeline Samson, Satoshi Morita, Moreno Ursino, Je´re´mie Guedj, Vincent
Jullien, Emmanuelle Comets, and Sarah Zohar. Unified approach for extrapolation and
bridging of adult information in early-phase dose-finding paediatric studies. Statistical
methods in medical research, 27(6):1860–1877, 2018.
[5] Satoshi Morita. Application of the continual reassessment method to a phase I dose-
finding trial in Japanese patients: East meets west. Statistics in Medicine, 30(17):2090–
2097, 2011.
[6] Yimei Li and Ying Yuan. PA-CRM: A continuous reassessment method for pediatric
phase I oncology trials with concurrent adult trials. Biometrics, pages 1–10, 2020.
[7] John O’Quigley, Margaret Pepe, and Lloyd Fisher. Continual reassessment method: a
practical design for phase 1 clinical trials in cancer. Biometrics, pages 33–48, 1990.
[8] James Babb, Andre´ Rogatko, and Shelemyahu Zacks. Cancer phase I clinical trials:
efficient dose escalation with overdose control. Statistics in Medicine, 17(10):1103–1120,
1998.
24
[9] Beat Neuenschwander, Michael Branson, and Thomas Gsponer. Critical aspects of the
bayesian approach to phase I cancer trials. Statistics in Medicine, 27(13):2420–2439,
2008.
[10] Guosheng Yin and Ying Yuan. Bayesian model averaging continual reassessment method
in phase I clinical trials. Journal of the American Statistical Association, 104(487):954–
968, 2009.
[11] Suyu Liu and Ying Yuan. Bayesian optimal interval designs for phase I clinical trials.
Journal of the Royal Statistical Society: Series C (Applied Statistics), 64(3):507–523,
2015.
[12] Yuan Ji, Ping Liu, Yisheng Li, and B Nebiyou Bekele. A modified toxicity probability
interval method for dose-finding trials. Clinical Trials, 7(6):653–663, 2010.
[13] Fangrong Yan, Sumithra J Mandrekar, and Ying Yuan. Keyboard: a novel bayesian
toxicity probability interval design for phase I clinical trials. Clinical Cancer Research,
23(15):3994–4003, 2017.
[14] Wentian Guo, Sue-Jane Wang, Shengjie Yang, Henry Lynn, and Yuan Ji. A bayesian
interval dose-finding design addressingockham’s razor: mtpi-2. Contemporary Clinical
Trials, 58:23–33, 2017.
[15] Ying Yuan, J Jack Lee, and Susan G Hilsenbeck. Model-assisted designs for early-phase
clinical trials: Simplicity meets superiority. JCO Precision Oncology, 3:1–12, 2019.
[16] Satoshi Morita, Peter F Thall, and Peter Mu¨ller. Determining the effective sample size
of a parametric prior. Biometrics, 64(2):595–602, 2008.
25
[17] Heng Zhou, Thomas A Murray, Haitao Pan, and Ying Yuan. Comparative review
of novel model-assisted designs for phase I clinical trials. Statistics in Medicine,
37(14):2208–2222, 2018a.
[18] Heng Zhou, Ying Yuan, and Lei Nie. Accuracy, safety, and reliability of novel phase I
trial designs. Clinical Cancer Research, 24(18):4357–4364, 2018b.
[19] Matthieu Clertant and John OQuigley. Semiparametric dose finding methods. Journal
of the Royal Statistical Society: Series B (Statistical Methodology), 79(5):1487–1508,
2017.
26
Number of patients treated at current dose (nj)
Pr
ob
ab
ilit
y
0.0
0.2
0.4
0.6
0.8
1.0
2 4 6 8
q =  0.10
PESS=5
q =  0.20
PESS=5
2 4 6 8
q =  0.30
PESS=5
q =  0.40
PESS=5
2 4 6 8
q =  0.50
PESS=5
q =  0.10
PESS=3
2 4 6 8
q =  0.20
PESS=3
q =  0.30
PESS=3
2 4 6 8
q =  0.40
PESS=3
0.0
0.2
0.4
0.6
0.8
1.0
q =  0.50
PESS=3
Non−informative prior in BOIN Informative prior in iBOIN
Figure 1: Escalation and de-escalation boundaries (λe, λd) of iBOIN given different prior
DLT probability (q) and PESS = 3 or 5, in comparison to the boundaries determined using
a non-informative prior in standard BOIN.
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Table 1: iBOIN decision boundaries up to 30 patients with a cohort size of 3, given the
skeleton (q1, · · · , q5) = (0.10, 0.19, 0.30, 0.42, 0.54) and PESS n01 = · · · = n05 = 3. The
target DLT probability φ = 0.3.
Number of patients treated at current dose
Dose level Action∗ 3 6 9 12 15 18 21 24 27 30
1
Escalate if no. of DLT ≤ 1 1 2 3 4 4 5 6 6 7
De-escalate if no. of DLT ≥ 2 3 4 5 7 8 9 10 11 12
2
Escalate if no. of DLT ≤ 0 1 2 3 3 4 5 5 6 7
De-escalate if no. of DLT ≥ 2 3 4 5 6 7 8 9 11 12
3
Escalate if no. of DLT ≤ 0 1 2 2 3 4 4 5 6 7
De-escalate if no. of DLT ≥ 2 3 4 5 6 7 8 9 10 11
4
Escalate if no. of DLT≤ 0 1 1 2 3 3 4 5 6 6
De-escalate if no. of DLT ≥ 1 2 3 4 6 7 8 9 10 11
5
Escalate if no. of DLT ≤ 0 0 1 2 2 3 4 5 5 6
De-escalate if no. of DLT ≥ 1 2 3 4 5 6 7 8 10 11
*When neither “Escalate” nor “De-escalate” is triggered, stay at the current dose for
treating the next cohort of patients.
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Table 2: Ten dose-toxicity scenarios with target DLT probability φ = 0.30. The prior
MTDs are correctly specified in scenarios 1-5 and misspecified in scenarios 6-10.
Dose level Dose level
1 2 3 4 5 1 2 3 4 5
Scenario 1 Scenario 6
True Pr(DLT) 0.30 0.42 0.50 0.60 0.65 0.09 0.12 0.15 0.30 0.45
Prior Pr(DLT) 0.30 0.42 0.54 0.64 0.73 0.01 0.04 0.10 0.19 0.30
Scenario 2 Scenario 7
True Pr(DLT) 0.15 0.27 0.40 0.50 0.65 0.08 0.15 0.31 0.45 0.55
Prior Pr(DLT) 0.19 0.30 0.42 0.54 0.64 0.19 0.30 0.42 0.54 0.64
Scenario 3 Scenario 8
True Pr(DLT) 0.08 0.15 0.31 0.45 0.55 0.08 0.15 0.31 0.45 0.55
Prior Pr(DLT) 0.10 0.19 0.30 0.42 0.54 0.01 0.04 0.10 0.19 0.30
Scenario 4 Scenario 9
True Pr(DLT) 0.09 0.12 0.15 0.30 0.45 0.04 0.08 0.10 0.18 0.27
Prior Pr(DLT) 0.04 0.10 0.19 0.30 0.42 0.04 0.09 0.30 0.40 0.45
Scenario 5 Scenario 10
True Pr(DLT) 0.05 0.08 0.10 0.14 0.30 0.08 0.10 0.28 0.40 0.45
Prior Pr(DLT) 0.01 0.04 0.10 0.19 0.30 0.30 0.42 0.54 0.64 0.73
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Table 3: Operating characteristics of iCRM, iBOIN and iKeyboard, in comparison with
their counterparts with non-informative priors. iBOINR and iKeyboardR are iBOIN and
iKeyboard using robust priors.
% Patients % Patients Risk of Risk of
Design PCS at MTD above MTD overdosing poor allocation
Scenario 1
CRM 54.8 59.9 27.8 23.2 12.2
iCRM 63.1 65.2 24.9 19.4 9.8
BOIN 59.2 59.6 29.0 23.6 10.2
iBOIN 64.2 66.2 22.4 12.8 4.5
iBOINR 64.2 66.2 22.4 12.8 4.5
Keyboard 59.2 59.3 29.3 23.6 10.2
iKeyboard 64.2 50.7 39.6 34.2 17.8
iKeyboardR 64.2 50.7 39.6 34.2 17.8
Scenario 2
CRM 51.6 36.1 7.7 29.5 25.2
iCRM 53.3 42.4 5.6 23.7 16.8
BOIN 50.6 41.1 6.0 23.0 17.1
iBOIN 57.8 47.6 3.7 10.4 8.6
iBOINR 57.8 47.6 3.7 10.4 8.6
Keyboard 50.2 41.1 6.0 23.0 16.7
iKeyboard 59.6 37.8 6.6 35.1 23.6
iKeyboardR 59.6 37.8 6.6 35.1 23.6
Scenario 3
CRM 57.2 37.8 22.1 17.3 21.6
iCRM 60.2 40.4 20.9 15.3 18.8
BOIN 52.3 35.6 17.0 7.9 19.2
iBOIN 59.8 41.3 14.5 3.5 10.9
iBOINR 58.9 38.2 17.7 9.1 15.2
Keyboard 52.4 35.7 17.1 7.9 18.9
iKeyboard 62.5 35.8 28.8 18.7 19.1
iKeyboardR 59.7 35.6 29.0 19.4 19.7
Scenario 4
CRM 52.0 30.0 15.3 10.3 33.4
iCRM 56.6 33.8 14.4 8.6 26.5
BOIN 51.5 28.6 13.1 1.2 24.6
iBOIN 59.7 36.0 12.1 0.6 12.8
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Table 3 Continued:
% Correct % Patients % Patients Overdose % Poor
Design selection at MTD above MTD (%) allocation
iBOINR 57.6 32.4 15.7 3.2 19.0
Keyboard 52.1 28.6 13.1 1.2 24.6
iKeyboard 65.1 31.7 25.6 11.2 18.9
iKeyboardR 62.4 31.7 25.6 11.2 18.9
Scenario 5
CRM 72.7 38.6 0 0 23.4
iCRM 75.8 41.7 0 0 19.7
BOIN 71.0 35.2 0 0 16.8
iBOIN 76.8 42.2 0 0 9.6
iBOINR 76.8 42.2 0 0 9.6
Keyboard 71.0 35.2 0 0 16.8
iKeyboard 75.8 47.1 0 0 5.2
iKeyboardR 75.8 47.1 0 0 5.2
Scenario 6
CRM 50.7 29.9 14.6 9.3 32.9
iCRM 57.3 33.8 17.0 13.0 28.2
BOIN 51.5 28.6 13.1 1.2 24.6
iBOIN 58.6 35.5 18.4 3.8 11.8
iBOINR 58.6 35.5 18.4 3.8 11.8
Keyboard 52.1 8.6 13.1 1.2 24.6
iKeyboard 59.5 9.2 27.9 11.2 17.9
iKeyboardR 59.5 9.2 27.9 11.2 17.9
Scenario 7
CRM 58.0 38.1 21.7 17.3 21.8
iCRM 59.8 38.0 18.3 13.4 21.3
BOIN 52.3 35.6 17.0 7.9 19.2
iBOIN 61.6 33.0 10.9 2.2 14.8
iBOINR 61.6 33.0 10.9 2.2 14.8
Keyboard 52.4 35.7 17.1 7.9 18.9
iKeyboard 56.4 45.4 15.3 3.6 6.8
iKeyboardR 56.4 45.4 15.3 3.6 6.8
Scenario 8
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Table 3 Continued:
% Correct % Patients % Patients Overdose % Poor
Design selection at MTD above MTD (%) allocation
CRM 57.8 37.0 21.6 17.2 22.9
iCRM 58.7 41.5 25.5 21.3 20.3
BOIN 52.3 35.6 17.0 7.9 19.2
iBOIN 54.3 36.2 28.6 19.9 19.8
iBOINR 54.3 36.2 28.6 19.9 19.8
Keyboard 52.4 35.7 17.1 7.9 18.9
iKeyboard 46.8 33.0 37.8 34.4 25.2
iKeyboardR 46.8 33.0 37.8 34.4 25.2
Scenario 9
CRM 67.5 36.5 0 0 30.0
iCRM 64.8 35.3 0 0 31.8
BOIN 69.4 33.8 0 0 22.4
iBOIN 51.4 25.7 0 0 35.3
iBOINR 68.8 36.7 0 0 21.2
Keyboard 69.4 33.8 0 0 22.4
iKeyboard 58.7 39.8 0 0 17.8
iKeyboardR 71.7 39.8 0 0 17.8
Scenario 10
CRM 54.2 36.5 0.0 28.3 26.1
iCRM 60.6 40.0 0.0 15.2 18.1
BOIN 53.1 37.5 5.3 14.6 17.2
iBOIN 65.5 36.1 0.5 3.1 13.4
iBOINR 65.5 36.1 0.5 3.1 13.4
Keyboard 52.6 37.5 5.3 14.6 17.1
iKeyboard 66.5 37.9 1.6 3.8 7.0
iKeyboardR 66.5 37.9 1.6 3.8 7.0
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Figure 2: Operating characteristics of iCRM, iBOIN, and iKeyboard, in comparison to their
counterparts with non-informative priors, under 2000 random scenarios when the prior is
correctly specified. iBOINR and iKeyboardR are iBOIN and iKeyboard using robust
priors, respectively. The number under each boxplot is the average value with the standard
deviation shown in parenthesis.
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Figure 3: Operating characteristics of iCRM, iBOIN and iKeyboard, in comparison to their
counterparts with non-informative priors, under 4000 random scenarios when the prior MTD
is one dose off from the true MTD. iBOINR and iKeyboardR are iBOIN and iKeyboard
using robust priors, respectively. The number under each boxplot is the average value with
the standard deviation shown in parenthesis.
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Figure 4: Operating characteristics of iCRM, iBOIN and iKeyboard, in comparison to their
counterparts with non-informative priors, under 4000 random scenarios when the prior MTD
is two doses off from the true MTD. iBOINR and iKeyboardR are iBOIN and iKeyboard
using robust priors, respectively. The number under each boxplot is the average value with
the standard deviation shown in parenthesis.
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Figure 5: Operating characteristics of iBOIN and iCRM when different amount of prior
information (i.e., PESS) is available for different doses under scenarios 1 to 5.
36
Appendix
A.1 Determining informative prior for BOIN
Suppose at dose level j, the prior estimate of DLT probability is qj with PESS of n0. This
prior information can be transformed into the prior distribution of the three hypothesis
employed by BOIN (i.e., H1j : pj = φ, H2j : pj = φ1, H3j : pj = φ2) as follows: for k = 1,
2 and 3,
pikj = Pr(Hkj | n0, qj)
=
n0∑
x=0
Pr(Hkj | x)Pr(x | n0, qj)
=
n0∑
x=0
Pr (x | Hkj) Pr (Hkj)∑3
k′=1 Pr (x | Hkj) Pr (Hkj)
Pr(x | n0, qj)
=
n0∑
x=0
Pr (x | Hkj)∑3
k′=1 Pr (x | Hkj)
Pr(x | n0, qj).
=
n0∑
x=0
φxk(1− φk)n0−x∑3
k′=1 φ
′x
k (1− φk′)n0−x
(
n0
x
)
qxj (1− qj)n0−x.
(A.1.1)
By doing so, the prior information is incorporated into the dose escalation and de-escalation
boundaries, as given by equation (2.3).
A.1
A.2 iBOIN Shiny app interface
Figure A.1: User interface of iBOIN software.
A.2
A.3 Random scenario configuration
A.3.1 Generate random scenarios where prior MTD is correctly
specified
To examine how the informative designs perform, we generated 2000 random scenarios with
the MTD located at dose level 1, 2, 3, 4, and 5, with equal probability. The random
scenarios were generated using the following pseudo-uniform algorithm [19]. Given a target
DLT probability φ and J dose levels,
1. Select one of the j ∈ (1, · · · , J) with probability 1/J .
2. Sample M ∼ Beta(max{J − j, 0.5}, 1).
3. Repeatedly sample J toxicity probabilities uniformly on [0, B] until these correspond
to a scenario in which dose level j is the MTD, where B = φ + (1 − φ) ×M is the
upper bound of DLT probability.
In these scenarios, the MTD is the dose with the DLT probability closest, but not nec-
essarily equal to the target φ. It is possible to obtain scenarios in which all of the doses
have DLT probabilities below or above the target φ. To ensure that MTD is uniquely and
meaningfully defined, we required that the true DLT probability of the MTD be within
[φ − 0.05, φ + 0.05], and the distance between the MTD and its adjacent doses be greater
than 0.05 and less than 0.3, i.e., 0.05 < pj+1 − pj < 0.3 and 0.05 < pj − pj−1 < 0.3. The
generating process was stopped until we obtained 2000 random scenarios that satisfied the
specification. Figure A.2 shows 50 scenarios from the 2000 random scenarios generated.
The plot shows that the scenarios cover a wide range of possible dose-toxicity scenarios that
we may encounter in practice. Each of the 2000 scenarios has their prior MTD correctly
specified. The five prior skeletons used are presented in scenarios 1-5 in Table 2.
A.3
Figure A.2: 50 randomly selected scenarios from the 2000 scenarios generated
A.4
A.3.2 Generate random scenarios with different levels of misspec-
ification
To assess the performance of the informative designs when the prior is misspecified (i.e.,
the prior MTD is not corresponding to the true MTD), we conducted extensive simulation
for random scenarios with different levels of severity for mis-specification. Below are the
configurations of the scenarios.
1. The prior MTD is one dose below the true MTD. Generate 2000 scenarios with
true MTD located at dose level 2, 3, 4, and 5 with equal probability. The corresponding
prior skeletons are in scenarios 1, 2, 3, and 4 in Table 2.
2. The prior MTD is one dose above the MTD. Generate 2000 scenarios with true
MTD located at dose level 1, 2, 3, and 4 with equal probability. The corresponding
prior skeletons are in scenarios 2, 3, 4, and 5 in Table 2.
3. The prior MTD is two doses below the true MTD. Generate 2000 scenarios with
true MTD located at dose level 3, 4, and 5 with equal probability. The corresponding
prior skeletons are in scenarios 1, 2, and 3 in Table 2.
4. The prior MTD is two doses above the MTD. Generate 2000 scenarios with true
MTD located at dose level 1, 2, and 3 with equal probability. The corresponding prior
skeletons are in scenarios 3, 4, and 5 in Table 2.
A.5
A.4 Simulation results for mixture prior under 10 sce-
narios in Table 2.
Table A.1 shows the performance of the iBOIN and iKeyboard designs when the mixture
prior was used. iBOINM50 and iBOINM90 denote iBOIN using mixture prior when the
weight assigned to the informative prior component is w = 0.5 and w = 0.9, respectively.
iKeyboardM50 and iKeyboardM90 are defined similarly. For ease of comparison, the results
of BOIN, iBOIN and iBOINR are replicated from Table 3. The results show that in general
mixture prior (e.g., iBOINM50 and iBOINM90) does not perform as well as the robust prior
(iBOINR).
Table A.1: Operating characteristics of iBOIN and iKeyboard designs with the mixture
priors.
% Patients % Patients Risk of Risk of
Design PCS at MTD above MTD overdosing poor allocation
Scenario 1
BOIN 59.2 59.6 29.0 23.6 10.2
iBOIN 64.2 66.2 22.4 12.8 4.5
iBOINR 64.2 66.2 22.4 12.8 4.5
iBOINM50 61.6 63.2 25.1 17.8 6.9
iBOINM90 63.2 65.8 22.5 13.1 5.3
Keyboard 59.2 59.3 29.3 23.6 10.2
iKeyboard 64.2 50.7 39.6 34.2 17.8
iKeyboardR 64.2 50.7 39.6 34.2 17.8
iKeyboardM50 59.1 54.2 34.9 29.4 13.5
iKeyboardM90 63.8 51.0 38.9 32.2 16.7
Scenario 2
BOIN 50.6 41.1 6.0 23.0 17.1
iBOIN 57.8 47.6 3.7 10.4 8.6
iBOINR 57.8 47.6 3.7 10.4 8.6
iBOINM50 53.8 44.4 4.8 16.2 11.3
iBOINM90 58.1 47.1 3.9 11.8 8.8
Keyboard 50.2 41.1 6.0 23.0 16.7
A.6
Table A.1 Continued:
% Correct % Patients % Patients Overdose % Poor
Design selection at MTD above MTD (%) allocation
iKeyboard 59.6 37.8 6.6 35.1 23.6
iKeyboardR 59.6 37.8 6.6 35.1 23.6
iKeyboardM50 52.5 39.2 7.1 29.3 20.7
iKeyboardM90 57.9 38.2 7.0 33.3 22.9
Scenario 3
BOIN 52.3 35.6 17.0 7.9 19.2
iBOIN 59.8 41.3 14.5 3.5 10.9
iBOINR 58.9 38.2 17.7 9.1 15.2
iBOINM50 57.0 39.7 14.7 4.0 13.9
iBOINM90 61.3 42.1 13.7 2.9 11.1
Keyboard 52.4 35.7 17.1 7.9 18.9
iKeyboard 62.5 35.8 28.8 18.7 19.1
iKeyboardR 59.7 35.6 29.0 19.4 19.7
iKeyboardM50 55.5 36.4 22.6 12.3 17.5
iKeyboardM90 62.0 36.2 26.8 16.1 19.3
Scenario 4
BOIN 51.5 28.6 13.1 1.2 24.6
iBOIN 59.7 36.0 12.1 0.6 12.8
iBOINR 57.6 32.4 15.7 3.2 19.0
iBOINM50 55.8 32.4 12.8 1.1 17.5
iBOINM90 60.4 35.8 12.2 0.9 12.9
Keyboard 52.1 28.6 13.1 1.2 24.6
iKeyboard 65.1 31.7 25.6 11.2 18.9
iKeyboardR 62.4 31.7 25.6 11.2 18.9
iKeyboardM50 56.5 30.4 19.4 5.2 21.6
iKeyboardM90 64.0 31.4 24.4 9.7 19.6
Scenario 5
BOIN 71.0 35.2 0 0 16.8
iBOIN 76.8 42.2 0 0 9.6
iBOINR 76.8 42.2 0 0 9.6
iBOINM50 72.8 38.0 0 0 12.8
iBOINM90 75.2 40.3 0 0 11.0
Keyboard 71.0 35.2 0 0 16.8
A.7
Table A.1 Continued:
% Correct % Patients % Patients Overdose % Poor
Design selection at MTD above MTD (%) allocation
iKeyboard 75.8 47.1 0 0 5.2
iKeyboardR 75.8 47.1 0 0 5.2
iKeyboardM50 73.2 41.7 0 0 8.9
iKeyboardM90 76.8 46.1 0 0 5.7
Scenario 6
BOIN 51.5 28.6 13.1 1.2 24.6
iBOIN 58.6 35.5 18.4 3.8 11.8
iBOINR 58.6 35.5 18.4 3.8 11.8
iBOINM50 55.6 32.3 16.1 3.2 17.9
iBOINM90 57.5 35.0 17.9 4.5 14.0
Keyboard 52.1 8.6 13.1 1.2 24.6
iKeyboard 59.5 9.2 27.9 11.2 17.9
iKeyboardR 59.5 9.2 27.9 11.2 17.9
iKeyboardM50 58.1 9.2 21.2 5.2 20.2
iKeyboardM90 60.1 0.2 26.9 9.7 18.3
Scenario 7
BOIN 52.3 35.6 17.0 7.9 19.2
iBOIN 61.6 33.0 10.9 2.2 14.8
iBOINR 61.6 33.0 10.9 2.2 14.8
iBOINM50 59.2 35.5 12.9 3.5 15.2
iBOINM90 61.1 33.6 10.2 2.0 14.6
Keyboard 52.4 35.7 17.1 7.9 18.9
iKeyboard 56.4 45.4 15.3 3.6 6.8
iKeyboardR 56.4 45.4 15.3 3.6 6.8
iKeyboardM50 57.6 40.9 15.5 4.9 10.7
iKeyboardM90 57.8 44.1 15.1 4.6 8.8
Scenario 8
BOIN 52.3 35.6 17.0 7.9 19.2
iBOIN 54.3 36.2 28.6 19.9 19.8
iBOINR 54.3 36.2 28.6 19.9 19.8
iBOINM50 54.8 37.0 22.6 12.2 18.1
iBOINM90 55.1 36.5 27.1 16.2 19.4
Keyboard 52.4 35.7 17.1 7.9 18.9
A.8
Table A.1 Continued:
% Correct % Patients % Patients Overdose % Poor
Design selection at MTD above MTD (%) allocation
iKeyboard 46.8 33.0 37.8 34.4 25.2
iKeyboardR 46.8 33.0 37.8 34.4 25.2
iKeyboardM50 51.9 35.3 28.0 18.1 18.2
iKeyboardM90 48.0 33.7 35.2 29.8 23.8
Scenario 9
BOIN 69.4 33.8 0 0 22.4
iBOIN 51.4 25.7 0 0 35.3
iBOINR 68.8 36.7 0 0 21.2
iBOINM50 59.5 28.6 0 0 30.7
iBOINM90 51.6 25.3 0 0 36.4
Keyboard 69.4 33.8 0 0 22.4
iKeyboard 58.7 39.8 0 0 17.8
iKeyboardR 71.7 39.8 0 0 17.8
iKeyboardM50 66.8 36.4 0 0 20.2
iKeyboardM90 62.3 38.7 0 0 18.3
Scenario 10
BOIN 53.1 37.5 5.3 14.6 17.2
iBOIN 65.5 36.1 0.5 3.1 13.4
iBOINR 65.5 36.1 0.5 3.1 13.4
iBOINM50 62.8 37.6 2.1 5.4 11.8
iBOINM90 64.9 36.9 0.6 2.6 12.3
Keyboard 52.6 37.5 5.3 14.6 17.1
iKeyboard 66.5 37.9 1.6 3.8 7.0
iKeyboardR 66.5 37.9 1.6 3.8 7.0
iKeyboardM50 61.7 38.0 3.2 7.1 9.6
iKeyboardM90 65.8 37.6 2.2 4.5 8.6
A.9
